|
CASPER
Compliance and quality of life study comparing once-daily controlled-release carvedilol and twice-daily immediate-release carvedilol in patients with heart failure
 |
Author(s) |
(a) Hauptman PJ, Pressler SJ, Sackner-Bernstein J, Ordronneau P, Udelson JE
(b) Udelson JE, Pressler SJ, Sackner-Bernstein J, Massaro J, Ordronneau P, Lukas MA, Hauptman PJ
|
 |
Title(s) |
(a) Rationale and design of CASPER: Compliance and Quality of Life Study Comparing Once-Daily Carvedilol CR and Twice-Daily Carvedilol IR in Patients with Heart Failure (b) Adherence with once daily versus twice daily carvedilol in patients with heart failure: the compliance and quality of life study comparing once-daily controlled-release carvedilol CR and twice-daily immediate-release carvedilol IR in patients with heart failure (CASPER) trial |
|
Reference(s) |
(a) Am J Cardiol 2006;98 Suppl:60L–6L
(b) J Card Fail 2009;15:385–93
|
|
Disease |
Heart failure |
|
Purpose |
To determine whether a once-daily formulation of carvedilol results in better compliance and increased patient satisfaction relative to a twice-daily formulation |
|
Study design |
Randomised, double-blind for comparison of controlled-release vs immediate-release carvedilol, open for comparison of controlled-release carvedilol once daily and usual twice-daily carvedilol, parallel-group |
|
Follow-up |
Aim 5 months |
|
Patients |
405 patients (133 carvedilol immediate-release, 136 carvedilol controlled-release once daily plus placebo once daily, 136 carvedilol controlled-release once daily), mean age 65 years, with mild to severe heart failure already receiving carvedilol immediate-release 6.25–25 mg bid |
|
Treatment regimen |
Carvedilol controlled-release, 20–80 mg/day once daily, or carvedilol immediate-release, 6.25–25 mg bid |
|
Results |
The primary endpoint of compliance did not differ between the double-blind carvedilol immediate release bid and the open-label carvedilol controlled-release once daily groups (89.3% vs 88.2%, 95% CI -4.4% to 6.6%; p = ns). There were no statistically significant differences in compliance between any of the three groups, nor differences in quality of life, treatment satisfaction or physiological measures among the three study arms
|
|
|
|
